Literature DB >> 19652604

Neurofibromatosis 2 [Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II].

D Gareth R Evans1.   

Abstract

Neurofibromatosis 2 is a dominantly inherited tumor predisposition syndrome caused by mutations in the NF2 gene on chromosome 22. Affected individuals inevitably develop schwannomas typically affecting both vestibular nerves leading to deafness. Rehabilitation with brainstem implants is improving this outcome. Schwannomas also occur on other cranial nerves, on spinal nerve roots, and on peripheral nerves. Meningiomas and ependymomas are other tumor features. In excess of 50% of patients represent new mutations and as many as one third are mosaic for the underlying disease causing mutation. Although truncating mutations (nonsense and frameshifts) are the most frequent germline event and cause the most severe disease, single and multiple exon deletions are common. A strategy for detection of the latter is vital for a sensitive analysis. NF2 represents a difficult management problem with most patients facing substantial morbidity and reduced life expectancy. Surgery remains the focus of current management, although watchful waiting and occasionally radiation treatment have a role. In the future, the development of tailored drug therapies aimed at the genetic level are likely to provide huge improvements for this devastating, life limiting condition.

Entities:  

Mesh:

Year:  2009        PMID: 19652604     DOI: 10.1097/GIM.0b013e3181ac9a27

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  40 in total

1.  Yes-associated protein 1 is activated and functions as an oncogene in meningiomas.

Authors:  Gilson S Baia; Otavia L Caballero; Brent A Orr; Anita Lal; Janelle S Y Ho; Cynthia Cowdrey; Tarik Tihan; Christian Mawrin; Gregory J Riggins
Journal:  Mol Cancer Res       Date:  2012-05-22       Impact factor: 5.852

Review 2.  The Hippo signaling pathway in stem cell biology and cancer.

Authors:  Jung-Soon Mo; Hyun Woo Park; Kun-Liang Guan
Journal:  EMBO Rep       Date:  2014-05-12       Impact factor: 8.807

Review 3.  Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds.

Authors:  A R M Ruhul Amin; Phillip A Karpowicz; Thomas E Carey; Jack Arbiser; Rita Nahta; Zhuo G Chen; Jin-Tang Dong; Omer Kucuk; Gazala N Khan; Gloria S Huang; Shijun Mi; Ho-Young Lee; Joerg Reichrath; Kanya Honoki; Alexandros G Georgakilas; Amedeo Amedei; Amr Amin; Bill Helferich; Chandra S Boosani; Maria Rosa Ciriolo; Sophie Chen; Sulma I Mohammed; Asfar S Azmi; W Nicol Keith; Dipita Bhakta; Dorota Halicka; Elena Niccolai; Hiromasa Fujii; Katia Aquilano; S Salman Ashraf; Somaira Nowsheen; Xujuan Yang; Alan Bilsland; Dong M Shin
Journal:  Semin Cancer Biol       Date:  2015-03-06       Impact factor: 15.707

4.  Pediatric neurofibromatosis type 2: clinical and molecular presentation, management of vestibular schwannomas, and hearing rehabilitation.

Authors:  Nicolas -Xavier Bonne; Rabih Aboukais; Marc Baroncini; Audrey Hochart; Pierre Leblond; Franck Broly; Frédérique Dubrulle; Jean-Paul Lejeune; Christophe Vincent
Journal:  Childs Nerv Syst       Date:  2016-10-04       Impact factor: 1.475

5.  EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma.

Authors:  Steven P Angus; Janet L Oblinger; Timothy J Stuhlmiller; Patrick A DeSouza; Roberta L Beauchamp; Luke Witt; Xin Chen; Justin T Jordan; Thomas S K Gilbert; Anat Stemmer-Rachamimov; James F Gusella; Scott R Plotkin; Stephen J Haggarty; Long-Sheng Chang; Gary L Johnson; Vijaya Ramesh
Journal:  Neuro Oncol       Date:  2018-08-02       Impact factor: 12.300

Review 6.  Current status and recommendations for imaging in neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis.

Authors:  Shivani Ahlawat; Jaishri O Blakeley; Shannon Langmead; Allan J Belzberg; Laura M Fayad
Journal:  Skeletal Radiol       Date:  2019-08-08       Impact factor: 2.199

7.  [Acoustic neuroma (vestibular schwannoma). Treatment from a neurosurgical perspective].

Authors:  U Schick; A Unterberg
Journal:  HNO       Date:  2011-01       Impact factor: 1.284

8.  Molecular Pathways: Hippo Signaling, a Critical Tumor Suppressor.

Authors:  Ana Sebio; Heinz-Josef Lenz
Journal:  Clin Cancer Res       Date:  2015-09-17       Impact factor: 12.531

9.  The Hippo signaling pathway and translational opportunities for brain cancers.

Authors:  Gilson S Baia; Otavia L Caballero; Gregory J Riggins
Journal:  CNS Oncol       Date:  2012-11

10.  Clinical outcome of neurofibromatosis type 2-related vestibular schwannoma: treatment strategies and challenges.

Authors:  Byung Sup Kim; Ho Jun Seol; Jung-Il Lee; Hyung Jin Shin; Kwan Park; Doo-Sik Kong; Do-Hyun Nam; Yang-Sun Cho
Journal:  Neurosurg Rev       Date:  2016-05-04       Impact factor: 3.042

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.